Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 15% IN WATER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure before irreversible renal failure occurs
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Terminal elimination half-life is approximately 0.25–1.5 hours in patients with normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Minimal hepatic metabolism; excreted unchanged by the kidneys.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Primarily renal excretion as unchanged drug; >97% eliminated by glomerular filtration within 24 hours. Minimal biliary/fecal elimination (<3%).
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Negligible (<5%) protein binding; does not bind significantly to albumin or other plasma proteins.
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
Volume of distribution is approximately 0.4–0.6 L/kg, confined primarily to extracellular fluid; little intracellular penetration.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Not applicable (NA) due to intravenous administration only; oral bioavailability is negligible (not absorbed).
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Contraindicated in anuria or severe renal impairment (e GFR < 10 m L/min); use with caution in mild to moderate impairment, monitor serum osmolarity and renal function.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No specific adjustment for Child-Pugh class; monitor for volume overload and electrolyte disturbances in severe hepatic impairment.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
IV infusion of 0.25-2 g/kg as a 15-20% solution over 30-60 minutes; dosing based on weight and clinical response.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Start at lower end of dosing range; monitor for fluid overload, electrolyte imbalances, and renal function due to age-related decreased reserve.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
None FDA-approved.
None.
Renal toxicity with high doses or prolonged use,Congestive heart failure exacerbation due to volume expansion,Electrolyte disturbances (hyponatremia, hypokalemia),Rapid infusion may cause hypotension and seizures,Use with caution in patients with anuria or pre-existing renal disease
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Anuria due to severe renal disease,Well-established anuria due to severe renal disease,Pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
No specific food interactions are documented. However, patients should maintain adequate hydration unless contraindicated. Diets high in sodium may exacerbate hypernatremia risk. Monitor fluid and electrolyte intake as directed by the clinician.
No clinically relevant food interactions.
Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that can cause maternal osmotic diuresis and fluid/electrolyte disturbances, potentially affecting fetal homeostasis. Risk in first trimester is unknown; in second and third trimesters, use only if clearly needed due to potential for maternal pulmonary edema or heart failure.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
It is unknown if mannitol is excreted in breast milk. In lactating women, breast-feeding is not recommended during IV infusion of high-dose mannitol due to possible infant exposure to high osmolar load. M/P ratio not available.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
No specific dose adjustments for pregnancy are established. Use with caution due to potential for altered renal function and fluid balance. Start with lowest effective dose, such as 50-100 g over 24 hours. Monitor closely for maternal volume overload.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
OSMITROL 15% IN WATER is a hypertonic solution for intravenous administration. Monitor serum sodium and osmolality closely to avoid hypernatremia and hyperosmolality. Ensure patency of IV line as extravasation can cause tissue necrosis. Use with caution in patients with renal impairment, heart failure, or hypovolemia. Rapid infusion can cause hemolysis. May cause osmotic diuresis leading to electrolyte depletion; monitor potassium and magnesium.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
This medication is given intravenously to reduce brain swelling or lower eye pressure.,Report any pain, redness, or swelling at the injection site immediately.,You may experience increased thirst or urination; this is expected due to the medication's effects.,Inform your healthcare provider if you have a history of kidney problems, heart failure, or dehydration.,Regular blood tests will be performed to monitor your electrolyte levels and kidney function.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 15% IN WATER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, answered by our medical review team.
OSMITROL 15% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 15% IN WATER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 15% IN WATER is: IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.. The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 15% IN WATER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 15% IN WATER is classified as Category C. Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that . MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.